Shares of NeurogesX Inc. plunged Thursday after the firm said a confirmatory Phase III study of its capsaicin dermal patch NGX-4010 missed its primary endpoint of providing statistically significant benefit in treating peripheral neuropathic pain in patients with HIV infection. (BioWorld Today)
Shares of NeurogesX Inc. plunged Thursday after the firm said a confirmatory Phase III study of its capsaicin dermal patch NGX-4010 missed its primary endpoint of providing statistically significant benefit in treating peripheral neuropathic pain in patients with HIV infection. (BioWorld Today)
More than 100 years after the creation of the FDA, the agency said it now will apply the same standards it uses in its premarket drug reviews to manage its post-marketing safety process. (BioWorld Today)
More than 100 years after the creation of the FDA, the agency said it now will apply the same standards it uses in its premarket drug reviews to manage its post-marketing safety process. (BioWorld Today)
